Aclaris Therapeutics, Inc. (NASDAQ:ACRS) insiders who sold US$1.6m worth of stock earlier this year are probably glad they did so as market cap slides to US$921m

July 04, 2022
Source: Shutterstock

Insiders seem to have made the most of their holdings by selling US$1.6m worth of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) stock at an average sell price of US$15.68 during the past year. The company's market valuation decreased by US$85m after the stock price dropped 8.4% over the past week, but insiders were spared from painful losses.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for Aclaris Therapeutics

The Last 12 Months Of Insider Transactions At Aclaris Therapeutics

The Co-Founder, Neal Walker, made the biggest insider sale in the last 12 months. That single transaction was for US$896k worth of shares at a price of US$15.91 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$13.83. So it may not tell us anything about how insiders feel about the current share price.

Insiders in Aclaris Therapeutics didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGS:ACRS Insider Trading Volume July 4th 2022

I will like Aclaris Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Does Aclaris Therapeutics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Aclaris Therapeutics insiders own about US$28m worth of shares. That equates to 3.0% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Aclaris Therapeutics Tell Us?

It doesn't really mean much that no insider has traded Aclaris Therapeutics shares in the last quarter. We don't take much encouragement from the transactions by Aclaris Therapeutics insiders. But we do like the fact that insiders own a fair chunk of the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aclaris Therapeutics. Case in point: We've spotted 4 warning signs for Aclaris Therapeutics you should be aware of, and 1 of these is potentially serious.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.